Cancer Letters

Cancer Letters

Volume 92, Issue 1, 25 May 1995, Pages 39-47
Cancer Letters

Increasing the number of tandem estrogen response elements increases the estrogenic activity of a tamoxifen analogue

https://doi.org/10.1016/0304-3835(95)03755-LGet rights and content

Abstract

There have been several reports of women who have tumor relapse while on tamoxifen therapy, followed by tumor regression after tamoxifen withdrawal. In such apparently tamoxifen-stimulated tumors, there is likely a genetic change which increases the estrogenicity of tamoxifen. In this study, we determine if increasing the number of estrogen response elements (EREs) in the promotor region of a reporter gene can alter the agonistic activity of fixed-ring 4-hydroxytamoxifen. We show that increasing the number of EREs in the promotor region increases the transcriptional response of the reporter plasmid to estradiol. We also find that while fixed-ring 4-hydroxytamoxifen is unable to stimulate transcription when one ERE is present, transcriptional activation can occur with multiple EREs. These results demonstrate that ERE amplification could explain the agonistic properties of tamoxifen, and suggests a novel mechanism to explain tamoxifen-stimulated breast cancer growth.

References (42)

  • Systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapy: 133 randomized trials involving 31 000 recurrences and 24 000 deaths among 75 000 women

    Lancet

    (1992)

    Systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapy: 133 randomized trials involving 31 000 recurrences and 24 000 deaths among 75 000 women

    Lancet

    (1992)
  • S. Legault-Poisson et al.

    Tamoxifen-induced tumor stimulation and withdrawal response

    Cancer Treat. Rep.

    (1979)
  • P.A. Canney et al.

    Clinical significance of tamoxifen withdrawal response

    Lancet

    (1987)
  • C.P. Belani et al.

    Tamoxifen withdrawal response: Report of a case

    Arch. Intern. Med.

    (1989)
  • A. Howell et al.

    Response after withdrawal of tamoxifen and progestogens in advanced breast cancer

    Ann. Oncol.

    (1992)
  • M.J.K. Harper et al.

    Contrasting endocrine activity of cis and trans isomers in a series of substituted triphenylethylenes

    Nature

    (1966)
  • L. Terenius

    Structure-activity relationships of antioestrogens with regard to interaction with 17 β-estradiol in the mouse uterus and vagina

    Acta Endocrinol.

    (1971)
  • R.L. Sutherland et al.

    Tamoxifen is a potent “pure” antioestrogen in the chick oviduct

    Nature

    (1977)
  • D.M. Wolf et al.

    Characterization of tamoxifen stimulated MCF-7 tumor variants grown in athymic mice

    Breast Cancer Res. Treat.

    (1994)
  • D.M. Wolf et al.

    The estrogen receptor from a tamoxifen-stimulated MCF-7 tumor variant contains a point mutation in the ligand-binding domain

    Breast Cancer Res. Treat.

    (1994)
  • Catherino, W. H. and Jordan, V. C. The biological action of cDNA's from mutated estrogen receptors translated into...
  • D.M. Wolf et al.

    Investigation of the mechanism of tamoxifen-stimulated breast tumor growth with non-isomerizable analogues of tamoxifen and metabolites

    J. Natl. Cancer. Inst.

    (1993)
  • S. Green et al.

    The oestrogen receptor: from perception to mechanism

  • C.M. Klinge et al.

    What differentiates antiestrogen-liganded vs. estradiol-liganded estrogen receptor action?

    Oncol. Res.

    (1992)
  • C.A. Campen et al.

    Opposing biological actions of antiestrogens in vitro and in vivo: induction of progesterone receptor in the rat and mouse uterus

    Endocrinology

    (1985)
  • J.F. Savouret et al.

    Characterization of the hormone responsive element involved in the regulation of the progesterone receptor gene

    EMBO J.

    (1991)
  • W.L. Kraus et al.

    Cloning of the rat progesterone receptor gene 5′-region and identification of two functionally distinct promotors

    Mol. Endocrinol.

    (1993)
  • H.D. Soule et al.

    A human cell line from a pleural effusion derived from a breast carcinoma

    J. Natl. Cancer Inst.

    (1973)
  • J.R. De Wet et al.

    Firefly luciferase gene: structure and expression in mammalian cells

    Mol. Cell. Biol.

    (1987)
  • S.K. Nordeen

    Luciferase reporter gene vectors for analysis of promoters and enhancers

    BioTechniques

    (1988)
  • L. Klein-Hitpaβ et al.

    An estrogen-responsive element derived from the 5′flanking region of the Xenopus vitellogenin A2 gene functions in transfected human cells

    Cell

    (1986)
  • Cited by (68)

    • Human glutathione S-transferase P1-1 functions as an estrogen receptor α signaling modulator

      2014, Biochemical and Biophysical Research Communications
      Citation Excerpt :

      The expression vector coding for GSTP (GenBank Accession No. NM_000852.3) was generated by inserting the 0.6 kbp long full-length GSTP into the EcoRI/BamHI sites of pIRESneo vector (Clontech, Mountain View, CA) to produce the pIRESneo/GSTP plasmid. The ERE-luciferase plasmid contains three copies of the Xenopus laevis vitellogenin A2 ERE upstream of the fire fly luciferase [13] and is a gift from Dr. V.C. Jordan (Lombardi Comprehensive Cancer Center, Georgetown University Medical Center, Washington, DC). The pSG5 plasmid containing the wild-type human ERα was originally engineered by Professor P. Chambon (Institut National de la Sante et de la Recherche Medicale, Strasbourg, France).

    • Tamoxifen Tales: Suggestions for Scientific Survival

      2022, Tamoxifen Tales: Suggestions for Scientific Survival
    View all citing articles on Scopus
    View full text